Document is current
Any future updates will be listed below
-
Authors
Martinez-Lemus, Juan D.
Molony, Donald A.
Suescun, Jessika
Tharp, Emily
Thomas, Tia S.
Green, Charles
Onuigbo, Chiamaka
Ritter, Robert III
Schiess, Mya C. https://orcid.org/0000-0001-9348-2587
-
Funding
Funding for this research was provided by:
Michael J. Fox Foundation for Parkinson's Research (MJFF-009634, MJFF-023299)
- License Information
-
More Information
Article History
Received: 15 May 2025
Accepted: 15 August 2025
First Online: 24 September 2025
Declarations
:
: Mya C. Schiess received financial support from the 2019 Clinical Therapeutic Pipeline Program Award by the Michael J. Fox Foundation for Parkinson’s Research (Grant ID: MJFF-009634 and MJFF-023299). All other authors declare no competing interests.
: The study titled “A Randomized, Double-Blind, Placebo-Controlled Trial of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells as a Disease-Modifying Therapy for Idiopathic Parkinson’s Disease” was approved by the Institutional Review Board (IRB) of the UTHealth Houston Committee for the Protection of Human Subjects (CPHS) under protocol number HSC-MS-20–0150, on April 8th, 2020. The protocol titled “Pilot Early – Phase I Study of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells Therapy for Idiopathic Parkinson’s Disease” for donor screening, bone marrow collection, and stem cell expansion was approved under protocol number HSC-MS-16–0026 on February 26th, 2016. Written informed consent was obtained from all participants for both study participation and the use of biological samples.
